Multivitamin/folic acid supplementation in early pregnancy reduces the prevalence of neural tube defects.
We examined the relation of multivitamin intake in general, and folic acid in particular, to the risk of neural tube defects in a cohort of 23,491 women undergoing maternal serum alpha-fetoprotein screening or amniocentesis around 16 weeks of gestation. Complete questionnaires and subsequent pregnancy outcome information was obtained in 22,776 pregnancies, 49 of which ended in a neural tube defect. The prevalence of neural tube defect was 3.5 per 1000 among women who never used multivitamins before or after conception or who used multivitamins before conception only. The prevalence of neural tube defects for women who used folic acid-containing multivitamins during the first 6 weeks of pregnancy was substantially lower--0.9 per 1000 (prevalence ratio, 0.27; 95% confidence interval, 0.12 to 0.59 compared with never users). For women who used multivitamins without folic acid during the first 6 weeks of pregnancy and women who used multivitamins containing folic acid beginning after 7 or more weeks of pregnancy, the prevalences were similar to that of the nonusers and the prevalence ratios were close to 1.0.
Milunsky
A
A
Center for Human Genetics, Boston University School of Medicine, MA 02118-2394.
Jick
H
H
Jick
S S
SS
Bruell
C L
CL
MacLaughlin
D S
DS
Rothman
K J
KJ
Willett
W
W
D000328:Adult; D000649:Amniocentesis; D005260:Female; D005492:Folic Acid / Q000008:administration & dosage*; D006801:Humans; D009436:Neural Tube Defects / Q000517:prevention & control*; D011247:Pregnancy; D011256:Pregnancy Outcome; D011261:Pregnancy Trimester, First; D011295:Prenatal Care; D012044:Regression Analysis; D011795:Surveys and Questionnaires; D014815:Vitamins / Q000008:administration & dosage*; D000509:alpha-Fetoproteins / Q000032:analysis
D014815:Vitamins; D000509:alpha-Fetoproteins; D005492:Folic Acid